Jakob B. Halpern represents clients in corporate, commercial, complex and multi-party litigation with an emphasis on intellectual property, employment, competition law, and professional malpractice matters, predominantly before the federal courts. He also counsels clients regarding intellectual property rights and employment issues.
Jake's clients range from well-known consumer brands and pharmaceutical companies to local businesses and individuals, and he has represented and counseled clients in diversified industries including pharmaceutical and healthcare, medical and chemical products, communications, insurance, distributorships, gaming, supermarkets and retailers, consumer electronic products, clothing and footwear, automotive, real estate, and other service and product industries.
Prior to joining Saiber, Jake clerked for the Hon. William Matthew Byrne, Jr., on the United States District Court for the Central District of California, following a year as a litigation associate at a prominent D.C. law firm. He has also served as producer on a successful cable television news program.
Forrester v. Prison Health Servs., 2015 WL 1469521 (E.D.N.Y. 2015), aff’d, 2015 WL 1469737 (E.D.N.Y. 2015), aff’d, 651 Fed. Appx. 27 (2d Cir. 2016) (granting and then affirming on appeal summary judgement for employer on Title VII, ADEA and FMLA claims).
Argush v. LPL Financial LLC, 2014 WL 3844822 (D.N.J. 2014) (granting motion to dismiss majority of claims in employment dispute), 2017 WL 349378 (D.N.J. 2017) (granting motion to strike expert reports and severely limiting potential damages).
Lugus IP, LLC v. Volvo Car Corp., 32 F. Supp. 3d 528 (D.N.J. 2014) (granting summary judgement of non-infringement of patent), 2015 WL 1399175 (D.N.J. 2015) (granting exceptional case motion and awarding attorney fees).
Am. Capital Acquisition Partners, LLC v. Fortigent LLC, 2014 WL 1210580 (D.N.J. 2014), aff’d, 595 Fed. Appx. 113 (3d Cir. 2014) (granting and affirming motion to dismiss tortious interference claims).
Assoc. of Am. Physicians & Surgeons, Inc. v. Am. Bd. of Med. Specialties, 2014 WL 1334260 (D.N.J. 2014) (granting motion to dismiss for improper venue and transferring matter).
Schering Corp. v. Apotex Inc., 2012 WL 2263292 (D.N.J. 2012) (bench opinion following trial finding no patent infringement by client).
Schering Corp. v. Mylan Pharmaceuticals Inc., 2011 WL 3736503 (D.N.J. 2011) (denying most aspects of opponent’s Summary Judgment Motion).
Marchese v. Cablevision Systems Corp., 2011 WL 3022529 (D.N.J. 2011), 2011 WL 149917 (D.N.J. 2011), 2010 WL 3311842 (D.N.J. 2010) (granting successive Motions to Dismiss original, Amended and Second Amended antitrust Complaints).
In re Wertheimer, 205 N.J. 87 (2011) (dismissal of formal ethics complaint against N.J. Superior Court judge following trial).
Banxcorp v. Apax Partners, L.P., 2011 WL 1253892 (D.N.J. 2011) (granting defendants’ Motion to Dismiss antitrust Complaint).
Laney v. American Standards Cos., 2010 WL 3810637 (D.N.J. 2010) (denying plaintiff’s Motion for Class Certification and granting in part defendant’s Motion for Summary Judgment).
Gardner v. U.S. Foodservice, Inc., 2010 WL 1050168 (D.N.J. 2010) (granting in part Motion to Dismiss discrimination Complaint).
Wyeth v. Abbott Laboratories, 692 F.Supp.2d 453 (D.N.J. 2010) (on appeal, reversing Magistrate Judge and determining cocounsel should not be disqualified from matter).
Bracco Diagnostics, Inc. v. Amersham Health, Inc.,627 F. Supp. 2d 384 (D.N.J. 2009) (trial opinion awarding injunction and damages to plaintiff).
TransUSA Products, Inc. v. Howard Berger Co., Inc., 2008 WL 3154753 (D.N.J. 2008), 2008 WL 852324 (D.N.J. 2008) (granting successive Motions to Dismiss unfair competition Complaints).
Allstate Ins. Co. v. Woods, 2008 WL 961240 (D.N.J. 2008) (denying defendants’ Summary Judgment Motion and granting client’s Cross-Motion disclaiming coverage under policy exclusion).
Gunvalson v. PTC Therapeutics, Inc., 2008 WL 4003377 (D.N.J. 2008) (entering preliminary injunction against a biotechnology company to enforce its promises to provide an investigational drug to a terminally ill teenager).